Search

Displaying results 901 - 910 of 6198 in total
  1. Drug

    Luliconazole

    go.drugbank.com/drugs/DB08933
    ApprovedInvestigational

    Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. … It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.

  2. Drug

    Canakinumab

    go.drugbank.com/drugs/DB06168
    ApprovedInvestigational

    Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). … be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by

  3. Drug

    Metandienone

    go.drugbank.com/drugs/DB13586
    ApprovedWithdrawn

    Metandienone is an orally active anabolic androgenic steroid. It was introduced to the market in the 1960s but later discontinued and withdrawn from the market. … [A254432] In the US, metandienone is a controlled substance under the Controlled Substances Act.[L44057]

  4. Drug

    Pancrelipase lipase

    go.drugbank.com/drugs/DB13147
    ApprovedInvestigational

    [L2509] The pancrelipase lipase is an enzyme secreted by the pancreas that is responsible for the hydrolysis of dietary fat molecules in the human digestive system. … [A32748] The pancrelipase mixture, including pancrelipase lipase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]

    Mixtures: Creon 8 Cap, Digess 8000 - Cap
  5. Drug

    Difenoxin

    go.drugbank.com/drugs/DB01501
    ApprovedIllicit

    It is approved by the FDA to treat acute and chronic diarrhea. … It works mostly in the periphery and activates opioid receptors in the intestine rather than the central nervous system (CNS). [3] Difenoxin is also closely related to loperamide, but unlike loperamide

  6. Drug

    Aminopterin

    go.drugbank.com/drugs/DB08878
    ApprovedWithdrawn

    In the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment of psoriasis. … Aminopterin is an amino derivative of folic acid, which was once used as an antineoplastic agent in the treatment of pediatric leukemia.

  7. Drug

    Phenindamine

    go.drugbank.com/drugs/DB01619
    Approved

    Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body.

  8. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    [A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010. … [A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism.[A2903] Unlike [clopidogrel], ticagrelor is not a prodrug.

  9. Drug

    Ipecac

    go.drugbank.com/drugs/DB13293
    ApprovedWithdrawn

    [L2753] Ipecac was approved by Health Canada as an OTC but all those products are now discontinued. … [L1113] The FDA does not have currently any approved product containing ipecac, however, ipecac as an ingredient is accepted to be sold over the counter in packages of 1 fluid ounce (30 ml) for the emergency

  10. Drug

    Baricitinib

    go.drugbank.com/drugs/DB11817
    ApprovedInvestigational

    [L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.